ECSP10010231A - Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. - Google Patents

Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.

Info

Publication number
ECSP10010231A
ECSP10010231A EC2010010231A ECSP10010231A ECSP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC 2010010231 A EC2010010231 A EC 2010010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A
Authority
EC
Ecuador
Prior art keywords
beta
selective inhibitors
derivatives
azaindol
dehydrogenase type
Prior art date
Application number
EC2010010231A
Other languages
English (en)
Inventor
Denis Carniato
Melanie Schultz
Didier Roche
Sophie Hallakou-Bozec
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010231A publication Critical patent/ECSP10010231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a derivados 7-azaindol de fórmula I, como inhibidores selectivos de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 (11?-HSD-1) y el uso de dichos compuestos para el tratamiento y prevención del síndrome metabólico, diabetes, resistencia a la insulina, obesidad, trastornos lipídicos, glaucoma, osteoporosis, trastornos cognitivos, ansiedad, depresión, trastornos inmunitarios, hipertensión y otras enfermedades y afecciones.
EC2010010231A 2007-11-05 2010-06-03 Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. ECSP10010231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291325 2007-11-05

Publications (1)

Publication Number Publication Date
ECSP10010231A true ECSP10010231A (es) 2010-07-30

Family

ID=40445347

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010231A ECSP10010231A (es) 2007-11-05 2010-06-03 Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.

Country Status (23)

Country Link
US (1) US8470849B2 (es)
EP (1) EP2247589B1 (es)
JP (1) JP5529743B2 (es)
KR (1) KR101624596B1 (es)
CN (1) CN101848910B (es)
AU (1) AU2008324525B2 (es)
BR (1) BRPI0819219B1 (es)
CA (1) CA2704803C (es)
CO (1) CO6270308A2 (es)
CY (1) CY1113645T1 (es)
DK (1) DK2247589T3 (es)
EA (1) EA019707B1 (es)
EC (1) ECSP10010231A (es)
ES (1) ES2400105T3 (es)
HR (1) HRP20130097T1 (es)
IL (1) IL205508A (es)
MX (1) MX2010004815A (es)
PL (1) PL2247589T3 (es)
PT (1) PT2247589E (es)
SI (1) SI2247589T1 (es)
UA (1) UA102379C2 (es)
WO (1) WO2009059666A1 (es)
ZA (1) ZA201004023B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2011247116B2 (en) * 2010-04-29 2015-12-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
CA3067746A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
AU2020407122A1 (en) * 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
WO2022006040A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth
US20240327400A1 (en) * 2020-06-30 2024-10-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
CN116546984A (zh) * 2020-09-28 2023-08-04 耶鲁大学 5-ht2a受体的选择性激动剂及其使用方法
CN112390815B (zh) * 2020-11-03 2022-07-26 浙江医药股份有限公司新昌制药厂 一种Lewis酸脱N-苄基制备d-生物素的制备方法
CN112409353A (zh) * 2020-11-27 2021-02-26 苏州艾缇克药物化学有限公司 一种7-氮杂吲哚衍生物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051837A2 (en) * 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
RS20060190A (sr) * 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
US20080015214A1 (en) * 2005-10-24 2008-01-17 Bignan Gilles C 3-piperidin-4-yl-indole orl-1 receptor modulators
US7638062B2 (en) 2006-07-10 2009-12-29 Cameron International Corporation Ultra compact cyclonic flotation system

Also Published As

Publication number Publication date
PL2247589T3 (pl) 2013-03-29
MX2010004815A (es) 2010-05-27
KR20100094500A (ko) 2010-08-26
EP2247589B1 (en) 2012-11-21
EA019707B1 (ru) 2014-05-30
DK2247589T3 (da) 2013-01-21
IL205508A0 (en) 2010-12-30
BRPI0819219A2 (pt) 2020-08-04
BRPI0819219B1 (pt) 2021-09-21
CN101848910B (zh) 2013-12-04
KR101624596B1 (ko) 2016-05-26
ZA201004023B (en) 2011-03-30
HRP20130097T1 (hr) 2013-02-28
CN101848910A (zh) 2010-09-29
EA201000751A1 (ru) 2010-12-30
SI2247589T1 (sl) 2013-03-29
JP5529743B2 (ja) 2014-06-25
US20100267761A1 (en) 2010-10-21
IL205508A (en) 2013-06-27
PT2247589E (pt) 2013-02-20
US8470849B2 (en) 2013-06-25
CA2704803A1 (en) 2009-05-14
EP2247589A1 (en) 2010-11-10
CO6270308A2 (es) 2011-04-20
UA102379C2 (ru) 2013-07-10
JP2011502135A (ja) 2011-01-20
CA2704803C (en) 2017-04-11
AU2008324525A1 (en) 2009-05-14
CY1113645T1 (el) 2016-06-22
ES2400105T3 (es) 2013-04-05
AU2008324525B2 (en) 2014-09-18
WO2009059666A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
ECSP10010231A (es) Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
CO6331305A2 (es) Nuevos derivados de nip tiazol como inhibidores de la 11-beta- hidroxiesteriode deshidrogenasa-1
BRPI0619839B8 (pt) derivados de 2-adamantiluréia, seu método de preparação e seus usos, composição farmacêutica, e kit
BRPI0606256A2 (pt) inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
ECSP088833A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
BRPI0606228A2 (pt) inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
CR11183A (es) Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CR20110255A (es) Nuevos compuestos 578
ECSP088839A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
UY32778A (es) Terapia de combinación para el tratamiento de la diabetes
UY32312A (es) 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
MX2011011082A (es) Derivados de amida y amidina novedosos y usos de los mismos.
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
ECSP088417A (es) Procedimientos para la preparacion de derivados de ciclopropilamida
EA201100419A1 (ru) Сопряженные пирролидино-циклопропановые производные в качестве селективных ингибиторов 11-бета-гидроксистероид дегидрогеназы 1 типа